Merck Says EMA’s CHMP Recommends Approval Of Expanded Enflonsia Indication To Prevent RSV In At-Risk Children Up To 24 Months Through Second RSV Season; EC Decision Expected Within Two Months
Merck Says EMA’s CHMP Recommends Approval Of Expanded Enflonsia Indication To Prevent RSV In At-Risk Children Up To 24 Months Through Second RSV Season; EC Decision Expected Within Two Months
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed